^
    Back
    Association details:
    Biomarker:ZFHX3 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Immunol
    Title:

    TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

    Published date:
    09/17/2021
    Excerpt:
    The top five altered genes, namely, ARID1A, ZFHX3, ATM, ARID2, and NTRK3, were named AZAAN. Therefore, we evaluated the effect of the predictor-AZAAN on responsive stratification in patients who had received immunotherapy. The results indicated that patients harboring AZAAN(+) received more OS benefits from immunotherapy than those patients harboring AZAAN(−) [AZAAN(+) vs. AZAAN(−): 22 months vs. 10 months, log-rank P value = 0.0006, HR = 0.59]...
    DOI:
    https://doi.org/10.3389/fimmu.2021.732125
    Test:
    MSK-IMPACT
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Immunol Immunother
    Title:

    ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer

    Published date:
    07/11/2020
    Excerpt:
    In the immunotherapy cohort (N = 350), ZFHX3 mutations were an independent predictive biomarker for NSCLC patients receiving ICI treatment. Significant differences were observed between ZFHX3-mutant (ZFHX3-MT) and ZFHX3-wild type (ZFHX3-WT) patients regarding the overall survival (OS) time (P < 0.001, HR = 0.26, 95% Cl 0.17-0.41).
    DOI:
    10.1007/s00262-020-02668-8